December 2013 HCV Advocate Newsletter (AASLD Edition)

Articles include: Focus on `Breakthrough Therapies` granted by the US FDA; AASLD Liver Meeting 2013 updates; HIV/HCV Coinfection; and Olysio (Simeprevir).

http://www.hcvadvocate.org/news/newsLetter/2013/advocate1213.html